Home PodcastInayet Wadee OUTA slams pathology groups for profiteering from the COVID-19 pandemic

OUTA slams pathology groups for profiteering from the COVID-19 pandemic

by Zahid Jadwat

JOHANNESBURG – Following the revelations by a Competition Commission investigation into the price of COVID-19 rapid antigen tests, the Organisation Undoing Tax Abuse (OUTA) has slammed private pathological groups for profiteering from the pandemic.

 

Speaking to Salaamedia, CEO of OUTA, Wayne Duvenage, condemned the “repulsive” conduct. He added that executives of companies involved in taking advantage of the situation must be held accountable.

 
“It’s quite diabolical this this conduct by these lab testing groups that really are not supposed to be profiteering out of a situation like this. No one denies the fact that business is here to make a profit but when you make excessive profits and when the complaints to the Competition Commission have to reveal that [the extent of price inflation] it’s actually rather worrying,” he said.
 
This week, the Competition Commission and three of South Africa’s largest private pathology groups – Pathcare, Lancet and Ampath – agreed on a price of R150 for the antigen rapid tests that were previously priced at R350. The stipulated price includes VAT.
 
The Commission’s investigation follows a complaint lodged by the Department of Health (DOH) against service providers delivering COVID-19 rapid antigen tests in South Africa to consumers.
 
Inayet Wadee spoke to Wayne Duvenage, CEO of the Organisation Undoing Tax Abuse (OUTA), on News & Views. Listen to the full discussion:

Related Videos